RxDoctor Payments Data

Tammy Dupuy, MD

Gynecology · Baton Rouge, LANPI 1629239983

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $561 of the $646 with a category attached, or 86.8%. It is spread thinly across 10 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $201 and has fallen 69.5% since, to $61 in 2025. That places this record below the midpoint for gynecology clinicians in LA, where the typical reported total is $879.

$646in general payments, 2019–2025

Across 17 payments — averaging $37.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dilon Technologies, Inc.$140
  • Genmab U.S., Inc.$110
  • Astellas Pharma US Inc$101
  • AstraZeneca$80
  • Dexcom, Inc.$61
  • Amgen$41
  • plus $112 from 4 others

What the payments were for

  • Food & beverage$56187%
  • Education$8513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$646 in reported general payments places this provider in the 40th percentile of 37 gynecology providers in Louisiana.

See all gynecology providers in Louisiana

Medicare billing

Part B allowed, 2024
$51,648
Medicare patients
305
Services billed
948

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab21$36,477
Estradiol303$14,831
PremarinEstrogens, Conjugated28$7,336
Estradiol (Twice Weekly)Estradiol67$7,317
ProgesteroneProgesterone, Micronized164$6,121
DottiEstradiol48$5,423
Estradiol (Once Weekly)Estradiol43$4,315
LyllanaEstradiol28$4,057
IntrarosaPrasterone (Dhea)15$3,812
Raloxifene Hcl48$2,672
ValacyclovirValacyclovir Hcl52$2,122
Ibandronate Sodium50$1,633
Clobetasol Propionate42$734
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet25$709
Acyclovir22$509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$41$36,47721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 37 gynecology providers in Louisiana.

Other gynecology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →